Cargando…

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deep...

Descripción completa

Detalles Bibliográficos
Autores principales: Osumi, Hiroki, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532210/
https://www.ncbi.nlm.nih.gov/pubmed/26273206
http://dx.doi.org/10.2147/OTT.S87101
_version_ 1782385197708214272
author Osumi, Hiroki
Matsusaka, Satoshi
Suenaga, Mitsukuni
Shinozaki, Eiji
Mizunuma, Nobuyuki
author_facet Osumi, Hiroki
Matsusaka, Satoshi
Suenaga, Mitsukuni
Shinozaki, Eiji
Mizunuma, Nobuyuki
author_sort Osumi, Hiroki
collection PubMed
description BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deepness of response (DpR) in patients treated with FOLFIRI plus C-mab. We aimed to evaluate the relationship between clinical outcome and DpR in metastatic colorectal cancer (mCRC) patients treated with second-line FOLFIRI plus C-mab. METHODS: A total of 112 patients with histopathologically confirmed mCRC treated with second-line FOLFIRI in combination with C-mab (N=42) or Bev (N=70) were retrospectively enrolled between October 2008 and June 2013. The relationship between DpR and clinical outcome in patients treated with FOLFIRI plus C-mab or Bev was determined. RESULTS: Forty-two patients treated with FOLFIRI plus C-mab had a mean DpR of 6.1% (inter-quartile range: −13.7%, 20.8%) and a minimum DpR of −62.7%. On the other hand, 70 patients treated with FOLFIRI plus Bev had a mean DpR of 0% (interquartile range: −16%, 10%) and a minimum DpR of −111%. DpR ≥30% was associated with significantly longer OS and PFS when compared with DpR ≤30% in patients given FOLFIRI plus C-mab. DpR (≥30%) was independently associated with prolongation of OS and PFS. In patients treated with FOLFIRI plus C-mab, there was a moderate positive correlation between DpR and clinical outcomes (OS: r=0.51, P<0.001; PFS: r=0.54, P<0.001). CONCLUSION: FOLFIRI plus C-mab yielded a stronger correlation between DpR and clinical outcomes. These results indicate the potential of DpR as a new measure of efficacy in mCRC patients treated with second-line chemotherapy plus C-mab.
format Online
Article
Text
id pubmed-4532210
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45322102015-08-13 Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab Osumi, Hiroki Matsusaka, Satoshi Suenaga, Mitsukuni Shinozaki, Eiji Mizunuma, Nobuyuki Onco Targets Ther Original Research BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deepness of response (DpR) in patients treated with FOLFIRI plus C-mab. We aimed to evaluate the relationship between clinical outcome and DpR in metastatic colorectal cancer (mCRC) patients treated with second-line FOLFIRI plus C-mab. METHODS: A total of 112 patients with histopathologically confirmed mCRC treated with second-line FOLFIRI in combination with C-mab (N=42) or Bev (N=70) were retrospectively enrolled between October 2008 and June 2013. The relationship between DpR and clinical outcome in patients treated with FOLFIRI plus C-mab or Bev was determined. RESULTS: Forty-two patients treated with FOLFIRI plus C-mab had a mean DpR of 6.1% (inter-quartile range: −13.7%, 20.8%) and a minimum DpR of −62.7%. On the other hand, 70 patients treated with FOLFIRI plus Bev had a mean DpR of 0% (interquartile range: −16%, 10%) and a minimum DpR of −111%. DpR ≥30% was associated with significantly longer OS and PFS when compared with DpR ≤30% in patients given FOLFIRI plus C-mab. DpR (≥30%) was independently associated with prolongation of OS and PFS. In patients treated with FOLFIRI plus C-mab, there was a moderate positive correlation between DpR and clinical outcomes (OS: r=0.51, P<0.001; PFS: r=0.54, P<0.001). CONCLUSION: FOLFIRI plus C-mab yielded a stronger correlation between DpR and clinical outcomes. These results indicate the potential of DpR as a new measure of efficacy in mCRC patients treated with second-line chemotherapy plus C-mab. Dove Medical Press 2015-08-06 /pmc/articles/PMC4532210/ /pubmed/26273206 http://dx.doi.org/10.2147/OTT.S87101 Text en © 2015 Osumi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Osumi, Hiroki
Matsusaka, Satoshi
Suenaga, Mitsukuni
Shinozaki, Eiji
Mizunuma, Nobuyuki
Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
title Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
title_full Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
title_fullStr Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
title_full_unstemmed Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
title_short Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
title_sort associations between deepness of response and clinical outcomes among japanese patients with metastatic colorectal cancer treated with second-line folfiri plus cetuximab
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532210/
https://www.ncbi.nlm.nih.gov/pubmed/26273206
http://dx.doi.org/10.2147/OTT.S87101
work_keys_str_mv AT osumihiroki associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab
AT matsusakasatoshi associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab
AT suenagamitsukuni associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab
AT shinozakieiji associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab
AT mizunumanobuyuki associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab